Activities

Patents

Re: OSURF 07087(4)
Polymorphisms in genes affecting CYP2CP-related disorders and uses thereof.
W Sadee, D Wang.
PCT US08/005539, filed April 30, 2008.
[corresp. to Ser. No. 60/926,932 filed April 30, 2007] Our file no.: 53-50099

Re: OSURF 07087(3)
Polymorphisms in genes affecting dopamine transporter disorders and uses thereof
W Sadee, A Papp, JK Pinsonneault
PCT US08/005556

Combination analgesic employing opioid and neutral antagonists. W Sadee, EJ Bilsky, J Yancey-Wrona. Application number 60/981/034. Filed October 18, 2007.

Invention Disclosure - Tech# ID 05087 (Ohio State University), March 2005: Prediction of anticancer drug potency from expression of genes involved in growth factor signaling. W Sadee and Z Dai.

Naltrexone derivatives with reduced C-6 position as neutral antagonists in the treatment of addiction and related applications. Provisional application US serial number 60/723502, October 2005.

US Patent No. 6,713,488: Neutral antagonists and the use thereof in treating drug abuse. W Sadee and D Wang, March 30, 2004. (Int. Appl. PCT/US01/08225).